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less than originally planned. Landry and Oliver 
propose a three-group trial (norepinephrine alone, 
vasopressin alone, and the two combined), which 
raises two concerns. First, the sample-size require-
ments for three-group trials are onerous — much 
greater than those for two-group trials. Second, 
treating patients with vasopressin alone would 
be difficult because norepinephrine is used rou-
tinely as the standard of care.5
Mogyorosi asks about the rate of hyponatre-
mia in VASST. Hyponatremia was recorded only 
if it was considered to be a serious adverse event, 
so the rate reported (0.3%) does not represent all 
cases of hyponatremia. Nonetheless, we found it 
reassuring that severe hyponatremia in the vaso-
pressin group was extremely rare and was not 
more frequent than in the norepinephrine group. 
We did not use an algorithm for hyponatremia; 
fluid and electrolyte levels were managed by clini-
cal teams at each center.
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Five Genetic Variants Associated with Prostate Cancer
To the Editor: We agree with Zheng et al. (Feb. 
28 issue)1 that additional research is needed to 
assess the value of their finding of genetic vari-
ants associated with the risk of prostate cancer. 
Unfortunately, the planned marketing of a test 
based on this study2 is premature and may cause 
more harm than good. Finding a genetic associa-
tion is only the first step in the continuum of 
translating research into practice.3 The results 
have not been independently confirmed, and add-
ing the genetic test results to age, region, and fam-
ily history only marginally improved risk predic-
tion (the area under the curve [AUC] increased 
from 0.61 to 0.63). The clinical utility of the test 
is questionable because it cannot be used to re-
duce risk, since there are no known modifiable 
risk factors4; to encourage screening, since the 
balance of benefits and harms is unknown5; or 
to predict the clinical course of the disease, since 
the variants were associated equally with aggres-
sive and nonaggressive cancers.1 In the absence 
of evidence of improved outcomes, this test may 
lead to unnecessary or potentially harmful pro-
cedures.
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To the Editor: In his accompanying editorial, 
Gelmann states that the five polymorphisms re-
ported by Zheng et al. do not yet constitute a vi-
able screening test.1 We think they never will. The 
use of genetic polymorphisms with modest odds 
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ratios (1.22 to 1.53 in the study by Zheng et al.) to 
screen for a polygenic disease such as prostate 
cancer is unlikely to be practical because most men, 
whether or not they have prostate cancer, will be 
at average genetic risk.2 In the study by Zheng et 
al., most case subjects and control subjects had one 
to three risk factors (85.5% of case subjects and 
86.2% of control subjects), and less than 10% of 
the case subjects were at high risk. A test based 
on these polymorphisms cannot distinguish ad-
equately between case subjects and control sub-
jects and will miss most cases or have false posi-
tive results for most controls (Table 1). This is 
reflected in the very poor AUC of the receiver-
operating-characteristic curve even when these 
genes are combined with other risk factors (AUC, 
0.63), which is not much better than that which 
is expected by chance (AUC, 0.50).
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To the Editor: Zheng et al. report that the com-
bined effect of family history and five single-
nucleotide polymorphisms (SNPs) on the risk of 
prostate cancer was increased by a factor of 9.46 
for men who had at least five factors as compared 
with those who had none. This contradicts the 
low discriminative accuracy they observed (AUC, 
0.63). For the calculation of this odds ratio, they 
compared the relatively small highest-risk category 
with the lowest-risk category. Selection of the low-
est-risk category as the reference is a frequently 
used and powerful approach to demonstrating an 
association,1,2 but it does not give a realistic im-
pression of the clinical usefulness of the findings. 
To evaluate the increase or decrease in the risk of 
disease as compared with the pretest or overall 
risk, we have recalculated the odds ratios, shown 
in Table 4 of the article, for number of associated 
factors as follows: no associated factors, 0.49 (ob-
served in 10% of the controls); one factor, 0.80 
(34%); two factors, 1.01 (36%); three factors, 1.34 
(17%); four factors, 2.35 (3%); and five or more fac-
tors, 4.78 (<1%). Although the findings of Zheng 
et al. are of great interest, their AUC analysis and 
a simple recalculation of their data show that the 
clinical implications are limited.
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To the Editor: The claim by Zheng et al. that 
five SNPs plus a family history “account for” 46% 
of cases of prostate cancer is misleading. They 
invoked the concept of population attributable 
fraction (PAF), not population attributable risk, 
as they incorrectly called it. PAF approximates the 
proportion of disease prevented by eliminating a 
risk factor.1 Its application to genetics is ques-
tionable.
None of the variants are known to be causal; 
elimination of the variants, even if possible, would 
not necessarily prevent prostate cancer. In any case, 
Table 1. Performance of a Screening Test for Prostate Cancer Based on Six Risk Factors (Five Genetic Polymorphisms 
plus Family History).
Test Cutoff  
(no. of risk factors)
Detection Rate  
(sensitivity)
False Positive Rate 
(1 − specificity)
Positive Predictive  
Value
Negative Predictive 
Value
percent
≥1 95.02 89.93 63.89 54.72
≥2 68.13 56.31 66.95 45.02
≥3 31.73 20.31 72.34 41.08
≥4 9.54 3.76 80.94 38.86
≥5 1.38 0.29 88.89 37.65
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PAF is highly dependent on the reference group.1 
A broader definition than the authors’ choice of 
men with no risk alleles (10% of controls) would 
lead to a lower PAF.
A better gauge of the effect of measured genes 
on a disease is the extent to which they explain 
the increased risk associated with having an af-
fected first-degree relative.2 With adjustment for 
the SNPs, the family-history effect went from 2.26 
(Table 1 of the article by Zheng et al.) to 2.22 
(Table 4 of the article), so they explained just 
2% of familial aggregation.
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To the Editor: Large-scale genomewide stud-
ies1 have identified risk alleles with low odds ratios 
that can have little clinical utility for risk predic-
tion. Zheng et al. combined genotypes to see 
whether the odds ratio can be increased to clini-
cally useful levels for estimating the risk of pros-
tate cancer. However, the authors did not compare 
the performance of the combined genotype with 
the current standard, prostate-specific antigen 
(PSA). Approximately 20% of their case subjects 
had a family history of prostate cancer, and 90% 
had a PSA level of more than 4 ng per milliliter; 
combining the two would probably have given a 
similar, if not better, population attributable risk. 
The addition of the combined genotype to age, 
region, and family history improved the AUC by 
a mere 3%, indicating lack of meaningful im-
provement over current methods. Finally, as with 
CHEK2 in breast cancer,2 the odds ratio is too 
low to be useful at such a low prevalence of the 
combined genotype. An increase in the odds ra-
tio obtained by combining genotypes comes at 
the price of a decline in the prevalence of the 
combined genotype.
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To the Editor: The model of Zheng et al. has 
limited predictive ability: using the data in Table 
4 of their article, we estimate an AUC of 0.57 for 
the SNPs. This is dwarfed by the AUC for a single 
PSA test at 44 to 50 years of age: in a large study 
of a representative, unscreened population, we re-
ported an AUC of 0.76 for the occurrence of pros-
tate cancer up to 25 years subsequently.1 More-
over, we have shown2 that a single PSA test can 
accurately predict advanced prostate cancer (AUC, 
0.79) and that screening decisions based on a sin-
gle PSA test before the age of 50 years are likely to 
lead to better outcomes for patients than the com-
peting alternative strategies of screening all or 
no men.3 As such, the proven technology of PSA 
testing currently offers by far the best method of 
stratifying men according to risk for prostate-
cancer screening.
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To the Editor: According to the data of Zheng 
et al., it could be expected that if very few per-
sons have none of the six risk factors they report 
(about 4%), then about 19% of the population 
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will have only one risk factor. On the basis of the 
hypothetical mean lifetime risk of prostate can-
cer of 10%, men with no risk factors might have 
less than a 4% lifelong risk, and men with only 
one risk factor less than a 6% lifelong risk. For 
these subgroups, the benefit of screening in rela-
tion to the risk is even more doubtful than it is in 
the general population.
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The authors reply: Our finding of a cumula-
tive effect of five genetic variants and family his-
tory on the risk of prostate cancer in a population-
based case–control study in Sweden was recently 
confirmed in two U.S. populations.1 The consis-
tent finding of a strong cumulative effect on pros-
tate-cancer risk, together with a relatively high 
frequency in the general population, calls for a 
new perspective in the interpretation and use of 
genetic information.
Until a perfect biomarker for predicting pros-
tate-cancer risk is available, there is a need to 
search for biomarkers that individually or col-
lectively offer some utility for risk prediction. We 
emphasize that our approach represents an ini-
tial but important step toward this goal. We found 
that a cutoff of three of these six risk factors had 
a specificity of 80% and a sensitivity of 32% for 
discriminating between case subjects and control 
subjects in this Swedish population. Although its 
specificity is lower than that of PSA (94%) with 
the use of a cutoff of 4.1 ng per milliliter, its sen-
sitivity is higher than that of PSA (21%).2 With 10 
additional risk variants reported since February 
2008, it is expected that the sensitivity and speci-
ficity will be further improved.
We do not advocate replacing the PSA test with 
genetic tests; we envision combining these tests 
to improve their predictive ability. Although we 
could not assess joint discriminatory performance 
because of our study design, we found that the 
cumulative effect of genetic risk factors is inde-
pendent of PSA levels and thus can provide com-
plementary information.
Just as men with a family history of prostate 
cancer are encouraged to start undergoing screen-
ing at an earlier age, men with multiple genetic 
risk factors might similarly be encouraged to be-
gin screening earlier. Unlike family history, which 
is subject to the limitations of family size, struc-
ture, current age of male relatives, and reliability 
of reporting, genetic markers can be accurately 
measured anytime.
Although it is difficult to provide risk informa-
tion with confidence for most men (who carry one, 
two, or three of the five genetic risk factors) by 
means of genetic markers alone, men who are at 
the two extremes in terms of the number of in-
herited factors may benefit substantially from 
categorization of their risk for prostate cancer.
Additional studies, especially prospective ones, 
are needed to further improve prediction of pros-
tate-cancer risk by including additional risk vari-
ants, combining them with PSA and other detec-
tion methods, and incorporating genetic markers 
that distinguish aggressive from nonaggressive 
prostate cancer in order to predict disease pro-
gression.
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Genetics of Warfarin Response
To the Editor: In the study reported by Schwarz 
et al. (March 6 issue),1 specific genetic variants 
related to warfarin metabolism reduced the time 
to the first therapeutic and supratherapeutic in-
ternational normalized ratio (INR) tests. A phar-
macogenetic-guided dosing algorithm for warfa-
rin,2 however, did not increase the time in the 
therapeutic range or reduce the proportion of su-
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